Denileukin Diftitox
Denileukin Diftitox-Cxdl is a targeted immunotherapy agent, likely a variant formulation of the fusion protein denileukin diftitox. It is designed to deliver a cytotoxic payload to cells expressing specific surface markers, primarily used in the treatment of certain hematologic malignancies. As a 'pin-variant' agent, it may represent a specific formulation or version optimized for particular clinical applications.
This is a targeted immunotherapy medication, possibly a specialized formulation variant, used primarily in treating certain blood cancers by delivering cytotoxic agents directly to cancer cells.
Key facts at a glance
- RxNorm
- 2700746
- Generic
- Denileukin Diftitox-Cxdl
- Class
- pin-variant
- Brands
- Lymphir
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Based on the denileukin diftitox base compound, this medication would likely be indicated for cutaneous T-cell lymphoma (CTCL) and potentially other T-cell malignancies expressing the CD25 (IL-2 receptor) marker. Specific indications for the Cxdl variant would depend on clinical trial data.
As a pin-variant of denileukin diftitox, this agent likely consists of a targeting domain (such as IL-2) fused to a cytotoxic payload (diphtheria toxin fragment). The targeting domain binds to receptors on target cells, facilitating internalization and delivery of the toxin, which inhibits protein synthesis and induces cell death.
The safety profile typically includes constitutional symptoms (fever, chills), vascular leak syndrome, hepatotoxicity, and hypersensitivity reactions. As the mechanism is not fully specified for this variant, clinicians should consult the complete prescribing information. Use requires careful patient selection based on biomarker expression (likely CD25). Pregnancy category C; breastfeeding should be avoided.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy